Genentech, the US-based biotech subsidiary of Swiss pharma major Roche, has announced the opening of the ‘Roche Genentech Innovation Centre Boston’. The centre focuses on work in cardiovascular, renal and metabolic (CVRM) diseases, and expands Roche and Genentech’s US research presence.
Located at Harvard’s Enterprise Research Campus in Allston, the centre brings together scientists from across discovery research, clinical development, artificial intelligence and data science disciplines. The centre complements established R&D teams in South San Francisco and Basel while connecting Roche and Genentech scientists more closely with researchers, talent and institutions across the Boston scientific and biotech ecosystem.
Even though CVRM diseases are closely interconnected, they have been traditionally studied and treated separately. By bringing work across these disease areas together, Roche and Genentech aim to better understand their shared biology and pursue more integrated approaches to treatment. This includes advancing therapeutic approaches across obesity and type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), hypertension and cardiovascular disease, with the goal of addressing underlying disease biology and delivering more holistic, long-term and personalised care.
AI, machine learning and data science will be an integral part of the research centre, with teams from Roche Product Development and Genentech Research and Early Development (gRED) working as part of an end-to-end R&D environment spanning discovery research through late-stage clinical development.
Roche and Genentech have signed a 10-year lease for the 95,000 square foot centre, which will have capacity for up to 500 people across research, clinical development, data science and other areas.
The innovation centre is part of Roche and Genentech’s $50-bn investment in US manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina and Hillsboro, Oregon. Roche and Genentech have approximately 25,000 employees in US, with 15 R&D centres and 13 manufacturing sites.


18 September, 2026 16:39:09 IST 

















